Aradigm Corporation has partnered with Professors Daniela Traini and Paul Young of the University of Sydney's Woolcock Institute of Medical Research to develop an aerosol nanoparticle technology to combat fungal and bacterial biofilms. The project will be funded by a A$420,000 grant from an Australian Research Council Linkage Project over three years. According to … [Read more...] about Aradigm and Woolcock Institute of Medical Research get grant for development of aerosol nanotechnology
News
3M’s Intelligent Control Inhaler wins CPhI award
The Intelligent Control Inhaler from 3M Drug Delivery Systems has won the drug delivery devices category of the CPhI Pharma Awards. According to CPhI, the inhaler was recognized "for its approach to addressing patient adherence and competence in Asthma and COPD patients" and is "an intuitive, fully integrated device delivering accurate doses to patients, whilst … [Read more...] about 3M’s Intelligent Control Inhaler wins CPhI award
Biocorp launches Inspair inhaler sensor
French device company Biocorp has announced the launch of its Inspair sensor, which it says is "capable of converting any pressurized metered dose inhaler into a connected device." According to the company, the sensor works with adaptors specially designed to fit the mouthpieces of most commonly marketed MDIs for asthma and/or COPD, and it records data on the … [Read more...] about Biocorp launches Inspair inhaler sensor
Chiesi submits MAA for triple combination inhaler
Chiesi Farmaceutici has submitted an MAA to the European Medicines Agency (EMA) for its extra-fine ICS/LABA/LAMA combination inhaler for the treatment of COPD. The submission is the first for a triple combination inhaler. In June 2016, Chiesi reported positive Phase 3 results for its beclamethasone/formoterol/glycopyrronium MDI, saying that it planned to submit an … [Read more...] about Chiesi submits MAA for triple combination inhaler
Health Canada approves Narcan nasal spray
Health Canada has approved Adapt Pharma's Narcan naloxone nasal spray for reversal of known or suspected opioid overdose. The approval comes three months after Health Canada announced that it would allow importation of Narcan nasal spray from the US, an order than remains in effect. Adapt says that it is working out distribution arrangements and will announce … [Read more...] about Health Canada approves Narcan nasal spray
OptiNose appoints Tom Gibbs as Chief Commercial Officer
OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal polyposis. Gibbs was most recently Senior VP and Head of the General Medicines Business Unit, US for Takeda. Gibbs said, “I … [Read more...] about OptiNose appoints Tom Gibbs as Chief Commercial Officer
Insmed appoints Roger Adsett as Chief Commercial Officer
Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time with AstraZeneca overseeing global marketing strategy for Rhinocort and Rhinocort Aqua. He was most recently Senior VP, Head of … [Read more...] about Insmed appoints Roger Adsett as Chief Commercial Officer
Mast Therapeutics to focus its efforts on AIR001
Mast Therapeutics has announced that it will stop its development program for vepoloxamer and will devote its resources to development of AIR001 sodium nitrite inhalation solution for patients with heart failure with preserved ejection fraction (HFpEF) and for pulmonary arterial hypertension (PAH). The company currently has 3 separate Phase 2 clinical trials of … [Read more...] about Mast Therapeutics to focus its efforts on AIR001
Simulations Plus joins SimInhale consortium
California-based simulation and modeling software company Simulations Plus has announced that it will join the SimInhale COST (European Cooperation in Science and Technology) Action consortium, which aims to "advance particle designs for improved deposition and interaction with lung tissue, promote realistic computer simulations of particle aerosolization, delivery … [Read more...] about Simulations Plus joins SimInhale consortium
Aegis Therapeutics gets patent for octreotide nasal spray
The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 ("Stabilizing alkylglycoside compositions and methods thereof") to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is used to treat acromegaly and carcinoid syndrome. In July 2014, Aegis Therapeutics announced that it was looking to … [Read more...] about Aegis Therapeutics gets patent for octreotide nasal spray